Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Durvalumab Plus BCG Improves DFS in High-Risk Non–Muscle-Invasive Bladder Cancer

May 9th 2025

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development

May 9th 2025

Challenges may arise as there could be unintended consequences on oncologic drug development, access, and innovation.

RAS(ON) Inhibitors May Overcome Resistance to Traditional KRAS Inhibitors in Solid Tumors

May 7th 2025

Study investigators are aiming to leverage therapy resistance, particularly in patients with solid tumors after receiving available RAS inhibitors.

Nivolumab/Ipilimumab Meets Primary OS End Point in Non–Clear Cell RCC

May 5th 2025

The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.

Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers

May 5th 2025

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Targeted Treatments Shift the Paradigm of Advanced BTC

May 5th 2025

During the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, an OncLive Peer Exchange® featured insights from expert investigators in the field of BTC.

Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC

May 2nd 2025

John V. Heymach, MD, PhD, discusses updated findings from the phase 1b Beamion LUNG-1 trial of zongertinib in HER2-mutated advanced NSCLC.

Patient Selection Is Crucial for Treatment Decisions in Metastatic Melanoma After PD-1 Inhibition

May 1st 2025

Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.

Adjuvant Anlotinib Displays Efficacy in High-Grade Soft Tissue Sarcoma

May 1st 2025

Adjuvant anlotinib was safe and led to a DFS benefit vs surgery alone in completely resected high-grade soft tissue sarcoma.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

April 29th 2025

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer

April 29th 2025

Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

April 29th 2025

Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.